Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a cyclical company: Graham number.
ACCE opinionCryoPort Inc. Common Stock (CYRX)
Fair value
Not available
ACCE price target
$15.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Price used: $17.98 at the close on 23 Oct 2026, 22:00 CEST.
Models: Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
44
out of 100
Analysts
89% buy
9 covering
P/E
0.0x
forward 79.4x
1-year return
+69.1%
Dividend yield
0.00%
CryoPort Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
CryoPort sells temperature-controlled logistics for cell and gene therapies, operating its Cryoport Express shippers and the CryoPort Express Freight, Storage and Tracking services that carry clinical and commercial biologics from manufacturer to clinic. The moat rests on validated, qualified shipping systems and the cold-chain tracking data built into them, which are hard to replicate quickly in a market where a failed shipment can ruin a patient's treatment. Revenue is growing at 7.7%, and with a 47.1% gross margin the business is clearly earning money on each unit it ships, but operating margin of -20.4% shows that overhead still swamps that gross profit. The forward P/E of 79.4 prices in a sizeable margin recovery that the current cost base has not yet demonstrated. The case for a deeper look rests on whether gene and cell therapy volumes ramp enough to cover fixed costs, so the first task is to model operating leverage on the next two years of shipment growth.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Negative free cash flow
Free cash flow is $-28.1M against a $883M market cap, with operating margin at -20.4% and net margin at -20.1%. The business is burning cash, not generating it.
moderate
Score falling over 90 days
The ACCE score fell from 53 to 45 over 90 days, with the growth pillar at 28 and value at 16. Earnings growth is flat at 0.0% YoY despite revenue up 7.7%.
moderate
Price above ACCE target
Insiders recorded $4.05M in sales and no buys across the last 10 disclosed transactions.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Analysts are largely positive, with 8 of 9 rating the stock Buy or Strong Buy.
Revenue has grown 17.5% per year on average over five years, showing a long record of expansion.
Return on invested capital of 8.8% shows the business earns a positive return on the money put into it.
Why it could disappoint
The company lost money on each sale, with a net margin of -20.1% in the latest filing.
Free cash flow over the last twelve months was -$28M, so the business consumed cash rather than generating it.
The diluted share count rose 2.7% last year, which spreads future profits across more shares.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where CYRX's valuation models land
Price
$17.98
Model fair valueConfidence: medium
$18.76
Model
Fair value
Upside
Graham number
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores